Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 2/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.62 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.62 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.62 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.62 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.62 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.62 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.62 |
| ▸ | CA2 | P00918 | 3/20 | 0.61 |
| ▸ | CA12 | O43570 | 2/20 | 0.61 |
| ▸ | CA9 | Q16790 | 2/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | CA1 | P00915 | 2/20 | 0.58 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.58 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.58 |
| ▸ | MMP1 | P03956 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11976711 | 0.89 | L3MBTL1 (0.77) | L3MBTL1EPHX1HPGDGAANPC1 | |
| Fenaclon SCHEMBL2109480 | 0.87 | HDAC3 (0.66) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| SCHEMBL10933092 | 0.87 | TRPV1 (0.73) | L3MBTL1HPGDGAANPC1RAB9A | |
| SCHEMBL7765076 | 0.86 | L3MBTL1 (0.79) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| SCHEMBL9336164 | 0.85 | EPHX1 (0.62) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| SCHEMBL11186772 | 0.84 | HDAC3 (0.62) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| SCHEMBL13619739 | 0.84 | HDAC3 (0.62) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| SCHEMBL4153733 | 0.84 | HPGD (0.79) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| SCHEMBL2186352 | 0.84 | HDAC2 (0.72) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| SCHEMBL7510811 | 0.84 | HDAC3 (0.71) | HDAC3HDAC1HDAC2HDAC10HDAC11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109336885-B | Preparation method of praziquantel | 周口师范学院 | 2021-04-13 | — | — | CN | claimed |
| US-8754215-B2 | Process for the preparation of praziquantel | SEQUENT SCIENTIFIC LIMITED (US) | 2014-06-17 | — | — | US | claimed |
| US-20130289275-A1 | PROCESS FOR THE PREPARATION OF PRAZIQUANTEL | SEQUENT SCIENTIFIC LIMITED (IN) | 2013-10-31 | — | — | US | claimed |
| EP-2651225-A2 | A PROCESS FOR PREPARATION OF PRAZIQUANTEL | Sequent Scientific Limited (IN) | 2013-10-23 | — | — | EP | claimed |
| CN-102059105-B | Oligopeptide-simulated CSP (Chiral Stationary Phase) and preparation method thereof | UNIV EAST CHINA SCIENCE & TECH | 2012-12-05 | — | — | CN | claimed |
| WO-2012081035-A2 | A PROCESS FOR PREPARATION OF PRAZIQUANTEL | SEQUENT SCIENTIFIC LIMITED (IN) | 2012-06-21 | — | — | WO | claimed |
| CN-102059105-A | Oligopeptide-simulated CSP (Chiral Stationary Phase) and preparation method thereof | UNIV EAST CHINA SCIENCE & TECH | 2011-05-18 | — | — | CN | claimed |
| EP-1641770-A4 | SYNTHESIS OF TRIS N-ALKYLATED 1,4,7,10-TETRAAZACYCLODODECANES | UNIV HONG KONG (CN) | 2008-12-31 | — | — | EP | claimed |
| EP-1641770-A1 | SYNTHESIS OF TRIS N-ALKYLATED 1,4,7,10-TETRAAZACYCLODODECANES | The University of Hong Kong (CN) | 2006-04-05 | — | — | EP | claimed |
| EP-1212056-B1 | METHODS AND COMPOSITIONS FOR BISUBSTRATE INHIBITORS OF ACETYLTRANSFERASES | US GOV HEALTH & HUMAN SERV (US) | 2005-12-07 | — | — | EP | claimed |
| WO-2005003105-A1 | SYNTHESIS OF TRIS N-ALKYLATED 1,4,7,10-TETRAAZACYCLODODECANES | THE UNIVERSITY OF HONG KONG (CN) | 2005-01-13 | — | — | WO | claimed |
| EP-1212056-A1 | METHODS AND COMPOSITIONS FOR BISUBSTRATE INHIBITORS OF ACETYLTRANSFERASES | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2002-06-12 | — | — | EP | claimed |
| US-20020002144-A1 | Methods and compositions for bisubstrate inhibitors of acetyltransferases | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2002-01-03 | — | — | US | claimed |
| WO-2001012185-A1 | METHODS AND COMPOSITIONS FOR BISUBSTRATE INHIBITORS OF ACETYLTRANSFERASES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-02-22 | — | — | WO | claimed |
| WO-2025243322-A1 | A PROCESS FOR PREPARATION OF PRAZIQUANTEL AND INTERMEDIATES THEREFOR | ALIVIRA ANIMAL HEALTH LIMITED (IN) | 2025-11-27 | — | — | WO | disclosed |
| CN-119431476-A | Novel anticancer drug TNBG-glycoconjugate and preparation and application thereof | 重庆医科大学 | 2025-02-14 | — | — | CN | disclosed |
| CN-117209453-A | Preparation and application of levocetirizine hydrochloride intermediate | 迪嘉药业集团股份有限公司 | 2023-12-12 | — | — | CN | disclosed |
| EP-0238357-A2 | 1,2,4-Triazinone derivatives, their preparation and use | Sankyo Company Limited (JP) | 1987-09-23 | — | — | EP | disclosed |
| US-4497952-A | Process for the production of (±)-4-oxo-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinoline derivatives | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 1985-02-05 | — | — | US | disclosed |
| EP-0017376-A1 | Phenylacetamide compounds and an analgesic composition containing them | KISSEI PHARMACEUTICAL CO. LTD (JP) | 1980-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130289275-A1 | PROCESS FOR THE PREPARATION OF PRAZIQUANTEL | CYP4B1, CYP2E1, CYP1A2 | HDAC3 1740/4885HDAC1 1539/4885HDAC2 1114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.